如何为 HIT 治疗给药和监测阿加曲班。

How to dose and monitor argatroban for treatment of HIT.

机构信息

Department of Pathology and Molecular Medicine (Division of Transfusion Medicine) and Department of Medicine (Division of Hematology and Thromboembolism), McMaster University, Hamilton, Ontario, Canada.

出版信息

Br J Haematol. 2022 Jun;197(6):653-655. doi: 10.1111/bjh.18153. Epub 2022 Apr 11.

DOI:10.1111/bjh.18153

PMID:35405030

Abstract

Dosing and monitoring of argatroban for treatment of heparin-induced thrombocytopenia (HIT) remain uncertain. Marchetti and colleagues critically and systematically reviewed their institutional experience using this direct thrombin inhibitor to treat patients with laboratory-confirmed HIT, and have formulated several practical recommendations for managing this challenging clinical situation. Commentary on: Marchetti et al. Managing argatroban in heparin-induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin-induced thrombocytopenia. Br J Haematol. 2022;197:766-790.

摘要

阿加曲班治疗肝素诱导的血小板减少症（HIT）的剂量和监测仍不确定。Marchetti 及其同事对其机构使用这种直接凝血酶抑制剂治疗经实验室证实的 HIT 患者的经验进行了批判性和系统性的回顾，并为处理这种具有挑战性的临床情况制定了一些实用建议。述评：Marchetti 等人。在肝素诱导的血小板减少症中管理阿加曲班：32 例确诊肝素诱导的血小板减少症患者 729 个治疗日的回顾性分析。英国血液学杂志。2022；197：766-790。